The hosts critique several "medical news" segments from ABC and NBC as thinly veiled native advertisements for Novo Nordisk and Pfizer. They point out that a pill version of semaglutide, Rybelsus, is already on the market for diabetes, but the current media blitz is focused on rebranding it specifically for weight loss. A Stanford doctor's claim that the drug is "safe and effective" is met with skepticism given the known side effects.
